5 not yet recruiting, 4 recruiting, 2 unknown, 1 active not recruiting. 14 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Not yet recruiting 5, Recruiting 4, Unknown 2, Active not recruiting 1, Completed 1, Withdrawn 1 |
| Phase 1 | 2 | Active not recruiting 1, Not yet recruiting 1 |
Follow Targeted therapy: new trials by email Literature Review of Targeted therapy trials Research Report on Targeted therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome Shuganhuazhuo Formula, Targeted therapy, Immunotherapy - HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine | Phase 2 | Not yet recruiting | Xiang-Qian | 120 | 2027-09-01 | 2026-08-27 |
| Testing Repeat Radiation Therapy for Recurrent Non-small Cell Lung Cancer Biospecimen Collection, Computed Tomography, Immunotherapy - Locally Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 | Phase 2 | Not yet recruiting | NRG Oncology | 138 | 2026-12-18 | 2026-09-23 |
| Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC Lenalidomide, Targeted Therapy, Immune Checkpoint Inhibitors - Hepatocellular Carcinoma (HCC) | Phase 2 | Recruiting | Shunda Du | 32 | 2026-08-12 | 2026-09-21 |
| TACE Combined With Thermal Ablation and ADC, PD-1, and Chemotherapy as First-line Treatment for HER2-highly-expressing Gastric Cancer With Liver Metastases: A Multicenter, Single-arm Prospective Clinical Study. TACE combined with thermal ablation, Targeted Therapy, Immunotherapy - Gastric Cancer With Liver Metastases | Phase 2 | Not yet recruiting | Shandong Provincial Hospital | 40 | 2026-08-01 | 2026-05-22 |
| A Prospective Study of Response-adapted Low-dose Radiotherapy Combined With Orelabrutinib for Localized Mucosa-associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma Radiation (Very low dose), Radiation (Standard) - Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) | Phase 2 | Not yet recruiting | Ruijin Hospital | 140 | 2026-08-01 | 2026-07-15 |
| Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma FOLFOX regimen, Immunotherapy, targeted therapy - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | BinYong Liang | 100 | 2026-04-30 | 2026-04-13 |
| A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma Tislelizumab, Afatinib, Lysogenic HSV virus. - HNSCC, Lysogenic HSV Virus | Phase 1 / Phase 2 | Active not recruiting | West China Hospital | 29 | 2025-06-10 | 2026-07-01 |
| Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer Serplulimab, Chemotherapy, SABR - Advanced Colorectal Carcinoma, Immunotherapy | Phase 2 | Recruiting | Fudan University | 208 | 2025-03-01 | 2025-03-14 |
| Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC Tislelizumab, Afatinib, Low dose radiotherapy - Head and Neck Cancer | Phase 2 | Withdrawn | West China Hospital | 2025-01-20 | 2025-11-19 | |
| Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients carbon ion radiotherapy, targeted therapy, single regimen chemotherapy in sequence with radiotherapy - Non-small Cell Lung Cancer, Older People | Phase 2 | Recruiting | Jian Chen | 29 | 2024-08-08 | 2025-06-13 |
| Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer Immunotherapy, Targeted therapy, Hyperthermia - Metastatic Castration-resistant Prostate Cancer (CRPC) | Phase 2 | Recruiting | Pengyuan Liu | 60 | 2024-01-01 | 2024-02-08 |
| Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma camrelizumab and apatinib - Chordoma, Chemotherapy Effect | Phase 2 | Unknown | Xuanwu Hospital, Beijing | 30 | 2023-10-30 | 2023-11-20 |
| HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC D-TACE, HAIC, Lenvatinib - Unresectable Hepatocellular Carcinoma | Phase 2 | Unknown | Wen Li | 60 | 2021-01-01 | 2022-10-17 |
| PLX3397 KIT in Acral aNd mucOsal Melanoma PLX3397 - Malignant Melanoma | Phase 2 | Completed | The Christie NHS Foundation Trust | 7 | 2015-10-01 | 2021-08-12 |
Carcinoma, Hepatocellular (3) · Carcinoma, Non-Small-Cell Lung (1) · Chordoma (1) · Head and Neck Neoplasms (1) · Hyperthermia (1) · Lung Neoplasms (1) · Lymphoma, B-Cell, Marginal Zone (1) · Melanoma (1) · Radiation Injuries (1) · Squamous Cell Carcinoma of Head and Neck (1)
West China Hospital (2) · BinYong Liang (1) · Fudan University (1) · Jian Chen (1) · NRG Oncology (1) · Pengyuan Liu (1) · Ruijin Hospital (1) · Shandong Provincial Hospital (1) · Shunda Du (1) · The Christie NHS Foundation Trust (1) · Wen Li (1) · Xiang-Qian (1) · Xuanwu Hospital, Beijing (1)
China (9) · United Kingdom (1)
Jingfang Mao, PHD (1) · Li Bing, PhD. (1) · Nitin Ohri (1) · Paul Lorigan, MBBCH, FRCP (1) · Shu-Bei Wang, MD (1) · Xingchen Peng (1) · Zan Chen (1)
PMID 23127803, PMID 34665942, PMID 37429302, PMID 38051328, PMID 39822559
U10CA180868 (1)